“I am pleased to mark this significant milestone, which reflects our organization’s unwavering commitment to quality and our continued focus on operational excellence,” said Bill Humphries, Chief Executive Officer of MedPharm. “For our valued clients—who rely on MedPharm for our proven innovation, technical expertise, and manufacturing leadership—this achievement further reinforces the strength of our topicals finished dosage manufacturing facility and our dedication to quality, compliance, and dependable execution.

“Receiving an FDA inspection outcome with no Form 483 issued and NAI classification is a powerful testament to the rigor of our Quality Systems and the discipline of our teams. With multiple products already filed from this facility, where we have recently added ICH compliant stability storage capabilities, we look forward to additional approvals as we continue expanding our manufacturing footprint and delivering exceptional value to our partners and the patients they serve.”

MedPharm’s purpose-built 110,000-square-foot facility in Durham accommodates research, development, analytical laboratories and robust quality assurance systems that complement the site’s CGMP clinical and commercial manufacturing capabilities for semi-solid dosage forms.
The company’s investors include Ampersand Capital Partners and Bourne Partners Strategic Capital.

About MedPharm
MedPharm is an end-to-end contract service provider of topical and transepithelial products supporting early-phase research, formulation development and in vitro testing services in addition to both clinical and commercial manufacturing. With its 2024 merger with Tergus Pharma, MedPharm enhanced its capabilities, transforming the business into a truly differentiated CDMO of scale with superior end-to-end capabilities from drug development and formulation to large batch commercial manufacturing and distribution. For more than 25 years, MedPharm has specialized in reducing risk through its unique, industry-leading in vitro testing and research biology models and is a global leader in product development for dermal/transdermal, lung and nasal, mucosal membrane, ungual, otic, and ophthalmic delivery. MedPharm has locations in the United Kingdom and the United States, including a new 110,000 sq. ft. state-of-the-art manufacturing facility in Durham, North Carolina. For more information, visit MedPharm.com or follow us on LinkedIn.

About Ampersand Capital Partners
Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. For additional information, visit Ampersandcapital.com or follow on LinkedIn.

About Bourne Partners Strategic Capital (“BPSC”)
Headquartered in Charlotte, N.C., Bourne Partners Strategic Capital is a private equity and growth equity investment firm focused exclusively on the pharmaceutical, pharma services and consumer healthcare sectors. As owners and operators with over 20 years of experience, BPSC has investment, strategic and operational experience in companies ranging from $5M to $3B in equity value and seeks to align and partner with management teams and other owners in these sectors to grow their businesses. BPSC is a related company of Bourne Partners, which offers investment banking and advisory services in the same key focus areas. For more information, please visit bourne-partners.com.

Media Contacts:
Sadie Smith, Marketing and Events Coordinator
E: sadie.smith@medpharm.com

Chris Halling, Director of Communications, Orientation Marketing
T: +44(0)7580 041073
E: chris.halling@orientation.agency